Nothing Special   »   [go: up one dir, main page]

DK1685243T3 - Immortaliserede fuglecellelinjer til virusproduktion - Google Patents

Immortaliserede fuglecellelinjer til virusproduktion

Info

Publication number
DK1685243T3
DK1685243T3 DK04798154T DK04798154T DK1685243T3 DK 1685243 T3 DK1685243 T3 DK 1685243T3 DK 04798154 T DK04798154 T DK 04798154T DK 04798154 T DK04798154 T DK 04798154T DK 1685243 T3 DK1685243 T3 DK 1685243T3
Authority
DK
Denmark
Prior art keywords
cell lines
immortalized
virus production
bird cell
production
Prior art date
Application number
DK04798154T
Other languages
English (en)
Inventor
Volker Sandig
Ingo Jordan
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1685243(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiogen Ag filed Critical Probiogen Ag
Application granted granted Critical
Publication of DK1685243T3 publication Critical patent/DK1685243T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10211Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10211Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251Methods of production or purification of viral material
    • C12N2710/10252Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04798154T 2003-11-03 2004-11-03 Immortaliserede fuglecellelinjer til virusproduktion DK1685243T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025158A EP1528101A1 (en) 2003-11-03 2003-11-03 Immortalized avian cell lines for virus production
PCT/EP2004/052789 WO2005042728A2 (en) 2003-11-03 2004-11-03 Immortalized avian cell lines for virus production

Publications (1)

Publication Number Publication Date
DK1685243T3 true DK1685243T3 (da) 2008-10-20

Family

ID=34400514

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04798154T DK1685243T3 (da) 2003-11-03 2004-11-03 Immortaliserede fuglecellelinjer til virusproduktion
DK08101999.4T DK1939281T4 (da) 2003-11-03 2004-11-03 Immortaliserede andecellelinjer til virusproduktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08101999.4T DK1939281T4 (da) 2003-11-03 2004-11-03 Immortaliserede andecellelinjer til virusproduktion

Country Status (18)

Country Link
US (2) US8940534B2 (da)
EP (4) EP1528101A1 (da)
JP (1) JP4658953B2 (da)
KR (1) KR101027755B1 (da)
CN (1) CN1934243B (da)
AT (2) ATE398672T1 (da)
AU (1) AU2004285089B2 (da)
BR (1) BRPI0415622B8 (da)
CA (1) CA2544462C (da)
CY (1) CY1110272T1 (da)
DE (2) DE602004014526D1 (da)
DK (2) DK1685243T3 (da)
ES (1) ES2309578T3 (da)
PL (1) PL1685243T3 (da)
PT (1) PT1685243E (da)
RU (1) RU2359999C2 (da)
SI (1) SI1685243T1 (da)
WO (1) WO2005042728A2 (da)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004257939B2 (en) * 2003-07-22 2008-06-05 Valneva Production of poxviruses with adherent or non adherent avian cell lines
PT1789084E (pt) 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
PL1951296T5 (pl) 2005-11-01 2015-06-30 Seqirus Uk Ltd Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
DK1951299T3 (da) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
CA2628158C (en) 2005-11-04 2015-12-15 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1783210A1 (en) * 2005-11-08 2007-05-09 ProBioGen AG Productivity augmenting protein factors, novel cell lines and uses thereof
ES2619160T7 (es) 2006-01-27 2020-07-29 Seqirus Uk Ltd Vacunas contra la gripe que contienen hemaglutinina y proteínas de la matriz
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2497495B3 (en) 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
AU2008270317B2 (en) * 2007-07-03 2013-12-05 Transgene S.A. Immortalized avian cell lines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
JP5653223B2 (ja) * 2008-02-25 2015-01-14 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 連続細胞系の生成方法
WO2009109377A1 (en) 2008-03-04 2009-09-11 Probiogen Ag Cell line from rousettus as host cell for pathogen amplification
EP2098590A1 (en) 2008-03-04 2009-09-09 ProBioGen AG Cell line from Rousettus as host cell for pathogen amplification
CN101998990B (zh) 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
EP2310494A1 (en) * 2008-06-25 2011-04-20 ProBioGen AG Cell line for propagation of highly attenuated alphaviruses
EP2199385A1 (en) 2008-12-16 2010-06-23 ProBioGen AG Specific and persistent activation of heat shock response in cell lines using a viral factor
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
JP5843615B2 (ja) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
CN105727281A (zh) 2009-02-10 2016-07-06 诺华股份有限公司 具有减少量的角鲨烯的流感疫苗
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
SI2396030T1 (sl) 2009-02-10 2015-12-31 Novartis Ag Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
JP5688373B2 (ja) * 2009-09-30 2015-03-25 国立大学法人帯広畜産大学 α−ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
ES2528010T5 (es) 2010-03-08 2018-02-19 Novartis Ag Métodos para detectar la presencia de patógenos intracelulares
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスb19のウイルス様粒子を生成するための方法
EP2563909A1 (en) 2010-04-26 2013-03-06 Novartis AG Improved production of virus replicon particles in packaging cells
JP6200805B2 (ja) 2010-05-03 2017-09-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
WO2011138682A2 (en) 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
KR20130081659A (ko) 2010-06-01 2013-07-17 노파르티스 아게 인플루엔자 백신 항원의 농축 및 동결건조
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
EP4098324A1 (en) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
US9453203B2 (en) 2010-11-02 2016-09-27 Helmholtz-Zentrum Fur Infektionsforschung Methods and vectors for cell immortalisation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
JP2014532620A (ja) 2011-10-20 2014-12-08 ノバルティス アーゲー 小児の初回免疫のためのアジュバント添加インフルエンザbウイルスワクチン
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
BR112015011389A2 (pt) 2012-11-20 2017-08-22 Glaxosmithkline Biologicals Sa Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
US20140193484A1 (en) 2013-01-10 2014-07-10 Sylvie Carine Bertholet Girardin Influenza virus immunogenic compositions and uses thereof
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
ES2778928T3 (es) 2013-08-30 2020-08-12 Glaxosmithkline Biologicals Sa Producción a gran escala de virus en cultivos celulares
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
US20150282503A1 (en) * 2014-04-02 2015-10-08 Synageva Biopharma Corp. Producing Therapeutic Proteins
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
HUE045108T2 (hu) 2014-07-16 2019-12-30 Transgene Sa Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására
MX2017007196A (es) 2014-12-04 2017-08-28 Intervet Int Bv Fibroblastos de embrion de pollo inmortalizados.
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
EP3234113B1 (en) 2014-12-16 2019-01-23 GlaxoSmithKline Biologicals S.A. A method for a large scale virus purification
RU2745567C2 (ru) 2014-12-17 2021-03-29 Фундасион Пара Ла Инвестигасион Медика Апликада Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
EP3744351A1 (en) 2014-12-17 2020-12-02 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
EP3764098B1 (en) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN107012122A (zh) * 2016-12-12 2017-08-04 江苏省农业科学院 一种永生化鸡胚胎肝细胞系及其制备方法和用途
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
EP3641803A2 (en) 2017-06-21 2020-04-29 Transgene Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University IMMUN REGULATORY MOLECULES AND THEIR USES
AU2018359420A1 (en) 2017-10-31 2020-06-04 Kalivir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
SG11202004926WA (en) 2017-12-01 2020-06-29 Encoded Therapeutics Inc Engineered dna binding proteins
US20210180084A1 (en) 2018-05-14 2021-06-17 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
WO2020012037A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110396496B (zh) * 2018-09-30 2023-06-20 湖北省农业科学院畜牧兽医研究所 一种鸭小肠上皮细胞的培养方法及应用
SG11202103681UA (en) 2018-10-12 2021-05-28 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
CN109321516A (zh) * 2018-11-07 2019-02-12 贵州大学 一种鸭原代肝细胞分离及培养方法
WO2020094693A1 (en) 2018-11-07 2020-05-14 Vivet Therapeutics Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
EP4257155A3 (en) 2018-11-16 2024-02-28 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
SG11202104869SA (en) 2018-11-23 2021-06-29 Valneva Se Food products comprising avian stem cells
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
EP3686276A1 (en) * 2019-01-28 2020-07-29 Freie Universität Berlin Production of viruses in continuously growing epithelial cell lines derived from chicken gut
EP3993871A1 (en) 2019-07-02 2022-05-11 Fundacion para la Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof
CA3146900A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
AU2020389047A1 (en) 2019-11-18 2022-06-02 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
EP4192961A2 (en) 2020-08-06 2023-06-14 Fundacion para la Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
CA3195052A1 (en) 2020-10-09 2022-04-14 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
EP4267197A1 (en) 2020-12-23 2023-11-01 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
JP2024502377A (ja) 2021-01-10 2024-01-18 スーパーミート ザ エッセンス オブ ミート リミテッド 培養肉産業用の多能性幹細胞凝集体及びそれから得られる微小組織
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
MX2023012608A (es) 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
EP4419650A1 (en) 2021-10-18 2024-08-28 Supermeat the Essence of Meat Ltd. Methods for preparing a food ingredient and compositions produced thereby
CN118434876A (zh) 2021-10-28 2024-08-02 Ucb生物制药有限责任公司 核酸构建体、病毒载体和病毒颗粒
CN114350601B (zh) * 2021-12-21 2022-12-27 广东省华晟生物技术有限公司 樱桃谷鸭成纤维细胞系及其构建方法与应用
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114908053A (zh) * 2022-04-24 2022-08-16 上海交通大学 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
CN116496992B (zh) * 2023-04-24 2023-12-01 江苏省家禽科学研究所 一种鸡胚成肌永生化细胞及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
KR970010968A (ko) 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2767335B1 (fr) 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CN1139655C (zh) * 2001-08-23 2004-02-25 北京大学人民医院 一种人卵巢癌永生化细胞株及其建立方法
CA2489301A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
MXPA04012966A (es) 2002-09-05 2005-05-16 Bavarian Nordic As Metodo para el cultivo de celulas primarias y para la amplificacion de virus bajo condiciones libres de suero.
AU2004257939B2 (en) 2003-07-22 2008-06-05 Valneva Production of poxviruses with adherent or non adherent avian cell lines

Also Published As

Publication number Publication date
ES2309578T3 (es) 2008-12-16
AU2004285089A1 (en) 2005-05-12
BRPI0415622A (pt) 2006-12-12
BRPI0415622B8 (pt) 2021-05-25
BRPI0415622B1 (pt) 2021-01-26
US20080227146A1 (en) 2008-09-18
CA2544462A1 (en) 2005-05-12
ATE398672T1 (de) 2008-07-15
WO2005042728A2 (en) 2005-05-12
DE602004014526D1 (de) 2008-07-31
RU2359999C2 (ru) 2009-06-27
EP1939281A1 (en) 2008-07-02
SI1685243T1 (sl) 2008-12-31
DK1939281T3 (da) 2010-06-14
AU2004285089B2 (en) 2009-07-02
EP1685243B1 (en) 2008-06-18
CN1934243A (zh) 2007-03-21
CY1110272T1 (el) 2015-01-14
EP1685243A2 (en) 2006-08-02
US20120288916A1 (en) 2012-11-15
ATE460473T1 (de) 2010-03-15
PT1685243E (pt) 2008-09-24
EP2192173A1 (en) 2010-06-02
WO2005042728A3 (en) 2005-07-07
DK1939281T4 (da) 2014-08-25
EP1939281B2 (en) 2014-06-04
PL1685243T3 (pl) 2008-12-31
KR20060123758A (ko) 2006-12-04
JP4658953B2 (ja) 2011-03-23
US8940534B2 (en) 2015-01-27
DE602004025996D1 (de) 2010-04-22
RU2006119447A (ru) 2007-12-20
CA2544462C (en) 2011-10-25
EP1939281B1 (en) 2010-03-10
CN1934243B (zh) 2011-07-06
KR101027755B1 (ko) 2011-04-07
JP2007510409A (ja) 2007-04-26
EP1528101A1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
DK1685243T3 (da) Immortaliserede fuglecellelinjer til virusproduktion
ATE466932T1 (de) Vermehrung von viren in zellkultur
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
ATE547511T1 (de) Nichttumorbildende mdck-zellinie zur vermehrung von viren
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CY1119106T1 (el) Αντισωματα εναντι masp-2
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
EA200970996A1 (ru) Стволовые клеточные линии, полученные из эмбрионов утки, для производства вирусных вакцин
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
ATE507242T1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EA201001045A1 (ru) Модифицированный вирус гриппа
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
CY1121438T1 (el) Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
AR024122A1 (es) Metodo para la estabilizacion intensificada de proteinas y produccion de lineas celulares que sirven para la produccion de dichas proteinas estabilizadas
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
WO2007019532A3 (en) Peptide aptamers that bind to the rep proteins of ssdna viruses
DK1537204T3 (da) Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller
DK1383796T3 (da) Neurovirulent stamme af viruset West Nile og anvendelser heraf
EA201201620A1 (ru) Способ получения рнк-вируса
EA201071226A1 (ru) Искусственный каркас белка
Koh et al. Expression of hepatitis C virus envelope glycoprotein E2 in transgenic rice cell suspension culture